My take from the recent reports was that Gilead has no fear to meet Abbvie wherever it wants to take the market. The guy who really got the raw deal was the express script customers who are locked into a single brand. It wouldn't surprise me if the Express doc's start warehousing their patients until next year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.